Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genotropin--a Miracle Medicine that Makes Dwarves Grow Tall (China)

This article was originally published in PharmAsia News

Executive Summary

Pfizer's Swedish branch Pfizer Strangnas produces Genotropin, a growth hormone used by around 65,000 patients around the world to enable them to grow normally. These patients lack a human growth hormone, and without this drug they would become dwarves as adults. Pfizer Strangnas site leader Simon Orchard says the company eventually may set up distribution and manufacturing operations in China if conditions for doing so remain competitive. He says China and India are potential sites. Orchard says that the patient pool for this drug remains larger than the current tapped field, at around 180,000 worldwide. Production already is expanding at current manufacturing facilities. Orchard compares today's pharmaceutical industry to the electronic and car industries of past decades, when manufacturing moved to Asia in order to remain competitive. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel